Nuage TherapeuticsBiotechnology - Therapeutics and Diagnostics
Nuage Therapeutics’ (NTx) mission is to leverage biomolecular condensation and chemical biology to develop selective inhibitors of intrinsically disordered proteins involved in challenging indications representing unmet medical needs. NTx is a spin-off from the Institute for Research in Biomedicine (IRB) and ICREA that arises from the laboratory of Molecular Biophysics lead by Dr. Xavier Salvatella at the IRB.
NTx has the expertise of Judit Anido as Co-founder and CEO; and of its three scientific founders: Dr. Xavier Salvatella; Dr. Denes Hnisz, leader of the Precision Gene Control group at the Max Planck Institute for Molecular Genetics in Berlin; and Dr. Mateusz Biesaga, specialist in biomedical engineering and responsible for assay development at NTx. NTx’s team also includes Dr. Jordina Guillén as Head of Research and Nadia Pons as Head of Corporate Development.